Astellas/FibroGen's anemia drug for CKD patients approved in Japan; Researchers propose combo to stay ahead of KRAS resistance
→ Roxadust, a treatment for anemia that arises as a complication in chronic kidney disease, has been approved in Japan. Developed by FibroGen and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
